Document:

Exhibit 10.1

 

EXECUTION VERSION

 

THIRD
Amendment TO 

right
of first offer agreement

 

This THIRD
Amendment TO right of first offer agreement, dated as of December 6, 2019 (this “Amendment”), amends
the Right of First Offer Agreement, dated as of August 31, 2018, and as subsequently amended on February 14, 2019 and August 1,
2019 (the “Agreement”), by and between CLEARWAY ENERGY GROUP LLC, a Delaware limited liability company (f/k/a
Zephyr Renewables LLC) (“Zephyr”), CLEARWAY ENERGY, INC., a Delaware corporation (f/k/a NRG Yield, Inc.) (“Yield”),
and GIP III Zephyr Acquisition Partners, L.P., a Delaware limited partnership (“Zephyr Parent”). Zephyr, Zephyr
Parent and Yield are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
Capitalized terms used herein and not otherwise defined shall have the meaning assigned to such terms in the Agreement.

 

WHEREAS, the Parties
have agreed to amend the Agreement as described herein.

 

NOW THEREFORE, the Parties
hereto, intending to be legally bound by this Amendment, agree as follows:

 

Section 1.01.         Amendments to the Agreement. Section 2.4(a) of the Agreement is hereby amended by adding the following at the end
of the second sentence thereof:

 

, less (d) the outstanding principal amount
of any indebtedness of any Person acquired by Yield pursuant to the exercise of the Carlsbad Purchase Option (excluding the aggregate
principal amount of the indebtedness under the Credit Agreement and the Note Purchase Agreement (as each are defined in the Carlsbad
Drop Down PSA)), plus (e) the balance at the time of exercise of the Carlsbad Purchase Option, assuming straight-line amortization
through the date of maturity of such indebtedness, of all fees, costs and expenses incurred in connection with the incurrence of
any such indebtedness (including, but not limited to, all upfront bank or placement fees, outside legal fees, independent engineer
fees and insurance consultant fees, but excluding interest), plus (f) the aggregate amount of all fees and cost reimbursements
incurred by GIP III Zephyr Carlsbad Holdings, LLC pursuant to Article 7 of that certain Master Services Agreement, dated July 1,
2019, by and between Clearway Energy Operating LLC and GIP III Zephyr Carlsbad Holdings, LLC.

 

Section 1.02.         Effectiveness of this Amendment. This Amendment is effective as of the first date set forth above.

 

Section 1.03.         No Other Changes. Except as expressly provided or contemplated by this Amendment, all of the terms, conditions and
provisions of the Agreement remain unaltered and in full force and effect. The Agreement and this Amendment shall be read and construed
as one agreement.

 

     

     

    

 

Section 1.04.        Facsimile; Counterparts. Each Party may deliver executed signature pages to this Amendment by facsimile or electronic
transmission to the other Parties, which facsimile or electronic copy shall be deemed to be an original executed signature page.
This Amendment may be executed in any number of counterparts, each of which shall be deemed an original and all of which counterparts
together shall constitute one agreement with the same effect as if the Parties had signed the same signature page.

 

Section 1.05.        
Governing Law. Section 5.7 of the Agreement shall apply, mutatis mutandis, to this Amendment.

 

Section 1.06.         Severability. If any term or provision of this Amendment is held to be or rendered invalid or unenforceable at any
time in any jurisdiction, such term or provision shall not affect the validity or enforceability of any other terms or provisions
of this Amendment, or the validity or enforceability of such affected terms or provisions at any other time or in any other jurisdiction.

 

    2

     

    

 

IN WITNESS WHEREOF, the undersigned have caused
this Amendment to be duly executed as of the date first above written.

 

	 	CLEARWAY ENERGY GROUP LLC

 

 

	 	By:	 /s/ Chad Plotkin

	 	Name:	 Chad Plotkin
	 	Title:	Chief Financial Officer

 

 

	 	CLEARWAY ENERGY, INC.

 

 

	 	By:	 /s/ Chad Plotkin

	 	Name:	Chad Plotkin
	 	Title:	Chief Financial Officer

 

 

	 	GIP III ZEPHYR ACQUISITION PARTNERS, L.P.

 

	 	By:	Global Infrastructure GP III, L.P., its general partner

 

	 	By:	Global Infrastructure Investors III, LLC, its general partner.

 

 

	 	By:	/s/ Jonathan Bram

	 	Name:	 Jonathan Bram
	 	Title:	 PresidentExhibit 10.1

 

AMENDMENT NO. 2

 

TO

 

DEVELOPMENT AND
SUPPLY AGREEMENT

 

This
Second Amendment (“2nd Amendment”) is made as of this 2nd day of December 2019
(the “Amendment Effective Date”) is between Trevena,
Inc. (“Trevena”) and the Pfizer
Centreone Group of Pfizer
Inc. (“Pfizer”).

 

Whereas,
Pfizer and Trevena are parties to that certain Development and Supply Agreement (the “Agreement”) dated
as of December 15, 2016 relating to the development, manufacture and supply by Pfizer for Trevena of Trevena’s proprietary
pharmaceutical compound, Oliceridine (“Product”);

 

Whereas,
in order to mitigate supply risks for the Product in accordance with Trevena’s business plan, the parties have determined
that it is in their mutual interests to proceed with a formal technical transfer plan fully to qualify the Pfizer Rocky Mount
facility as the site for the manufacture of the Product;

 

Whereas,
Pfizer is in agreement fully to support the technical transfer plan and to implement the plan as soon as possible;

 

Whereas,
in order to undertake and complete the mitigation plan, that Parties have agreed to modify the Agreement to regarding mutual rights
of termination as provided herein; and

 

Whereas,
Pfizer and Trevena wish to amend the Agreement to reflect their mutual agreement, as provided in this 2nd
Amendment.

 

Now,
Therefore, in consideration of the mutual covenants, conditions
and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, Pfizer and Trevena agree as follows:

 

		1.	Capitalized terms used but not defined herein shall have
the meanings set forth in the Agreement.

 

		2.	Definitions.

 

		a.	Section 1.10 is hereby amended by replacing the existing definition in its entirety with
the following new definition:

 

“Commercial
Year” means each period of twelve (12) consecutive calendar months during this Agreement beginning on January 1st
and ending December 31st, except for the first Commercial Year, which
shall commence on the first day of the month after the month in which Trevena makes its first bona fide commercial sale
of a Product manufactured by Pfizer in accordance with this Agreement to a non- Affiliate customer and ends on December 31st
of the following year.

 

CERTAIN IDENTIFIED INFORMATION
HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
OMISSIONS ARE DESIGNATED [***]

 

     

     

    

 

		b.	Section 1.21 is hereby amended by replacing the existing definition in its entirety with
the following new definition:

 

“Facility”
means Pfizer's pharmaceutical manufacturing plant at Rocky Mount, North Carolina or such other manufacturing facility agreed by
the parties in writing.”

 

 3.     
 Section 10.3 (General Termination Rights). The Parties hereby agree to delete Section 10.3(a) of the Agreement in its entirety and to replace it with the following amended provisions:

 

Either Party may terminate
this Agreement:

 

“(a) Failure
to Obtain Regulatory Approval. Upon [***] days written notice if the FDA or other relevant Regulatory Authority does not
grant Regulatory Approval for the Product by December 31, 2021; or”

 

4.     
Supplemental Statement of Work. A new Statement of Work, No. [***] is hereby added to this Agreement in the form
as attached hereto as Annex A, attached hereto. The goal of the project is to wind-down, cease and transfer all development
and manufacturing work on the Trevena Products from the McPherson Facility to the Rocky Mount Facility. Pfizer will ensure that
technical transfer work to be carried out under Statement of Work No. [***] shall be done in a professional and business-like manner,
including the manufacturing of stability, validation and registration batches of Products thereunder and that such manufacturing
will be in accordance with the Manufacturing Process and the Specifications as transferred from Trevena to Pfizer under the Agreement.

 

5.     
All other terms and conditions of the Agreement shall remain in full force and effect and are hereby ratified and confirmed.

 

6.     
In the event that there are any conflicts between the terms of this 2nd
Amendment and the terms of the Agreement, the terms of this 2nd Amendment shall
control. The terms of this 2nd Amendment shall be controlling over any terms of
any purchase order, sales acknowledgement, invoice or other such documents issued by either party.

 

7.     
This 2nd Amendment may be executed in two or more counterparts, each of
which shall be deemed to be an original, and all of which shall together constitute one and the same agreement.

 

8.     
Delivery of a signed 2nd Amendment by reliable electronic means, including
facsimile or email, shall be an effective method of delivering the executed 2nd
Amendment. This 2nd Amendment may be stored by electronic means and either an
original or an electronically stored copy of this 2nd Amendment can be used for
all purposes, including in any proceeding to enforce the rights and/or obligations of the parties to this 2nd
Amendment.

 

SIGNATURE PAGE FOLLOWS

 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS
EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED
[***]

 

     

     

    

 

In
Witness Whereof,
the parties hereto have caused their authorized representatives to execute this 2nd
Amendment as of the Amendment Effective Date.

 

	PFIZER CENTREONE PFIZER, INC.	 	TREVENA, INC.
	 	 	 
	By:	/s/ Thomas P Wilson 	 	By:	/s/ Mark A Demitrack MD 
	 	(Signature)	 	 	(Signature)
	 	 	 
	Name:	Thomas P Wilson	 	Name:	Mark A Demitrack MD
	 	 	 	 	 
	Title:	Pfizer CenterOne Contract Manufacturing Business Leader	 	Title:	Chief Medical Officer

 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS
EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED
[***]

 

     

     

    

 

 

 

Statement of Work NO. [***]

 

[***] (7 pages omitted)

 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS
EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. OMISSIONS ARE DESIGNATED
[***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]